INTERVENTION 1:	Intervention	0
Cohort 1 (Safety Analysis Set)	Intervention	1
Subjects received MBV twice weekly by subcutaneous injection at a starting dose of 250 EU (dose level 1), with intrasubject dose escalations for each subsequent administration in the absence of a DLT until the desired pyrogenic effect was observed.	Intervention	2
INTERVENTION 2:	Intervention	3
Cohort 2 (Safety Analysis Set)	Intervention	4
Subjects received MBV twice weekly by intralesional (preferred) or subcutaneous (if intralesional not possible) injection at the fixed dose (60,800 EU [dose level 6]) that was determined to be the pyrogenic dose level in Cohort 1.	Intervention	5
Inclusion Criteria:	Eligibility	0
Histologically confirmed metastatic melanoma, head and neck cancer, transitional cell carcinoma, sarcoma, gastrointestinal stroma tumor (GIST) or prostate cancer.	Eligibility	1
melanoma	HP:0002861,DOID:1909	36-44
head and neck cancer	DOID:11934	46-66
transitional cell carcinoma	DOID:2671	68-95
sarcoma	HP:0100242,DOID:1115	97-104
gastrointestinal stroma tumor	HP:0100723	106-135
prostate cancer	HP:0012125,DOID:10283	146-161
Tumor expression of NY-ESO-1 by reverse transcriptase and polymerase chain reaction (RT-PCR) analysis, preferably, or immunohistochemistry.	Eligibility	2
polymerase chain reaction	BAO:0002080	58-83
immunohistochemistry	BAO:0000415	118-138
Expected survival of at least 6 months.	Eligibility	3
Karnofsky performance status  70%.	Eligibility	4
Fully recovered from surgery.	Eligibility	5
surgery	OAE:0000067	21-28
Declined, intolerated or completed standard therapy defined as follows for each tumor entity:	Eligibility	6
Melanoma - resistance or intolerance to dacarbazine.	Eligibility	7
melanoma	HP:0002861,DOID:1909	0-8
dacarbazine	CHEBI:4305	40-51
Sarcoma - resistance or intolerance to anthracyclines and to one platinum-containing chemotherapy regimen, no indication for irradiation.	Eligibility	8
sarcoma	HP:0100242,DOID:1115	0-7
GIST - failure or intolerance of imatinib and sunitinib.	Eligibility	9
imatinib	CHEBI:45783	33-41
sunitinib	CHEBI:38940	46-55
Head and neck cancer - no indication for irradiation, resistance or intolerance to platinum-containing chemotherapy.	Eligibility	10
head and neck cancer	DOID:11934	0-20
Transitional cell carcinoma - resistance or intolerance to cisplatin combined with gemcitabine.	Eligibility	11
transitional cell carcinoma	DOID:2671	0-27
cisplatin	CHEBI:27899	59-68
gemcitabine	CHEBI:175901	83-94
Prostate cancer- failure of antihormonal treatment and resistance or intolerance to docetaxel.	Eligibility	12
Ovarian carcinoma - failure of standard chemotherapy consisting of a platinum agent combined with a taxane and of an anthracycline.	Eligibility	13
ovarian carcinoma	HP:0025318,DOID:4001	0-17
platinum	CHEBI:33364	69-77
taxane	CHEBI:36064	100-106
anthracycline	CHEBI:48120	117-130
Esophageal cancer - failure of standard chemotherapy consisting of a platinum agent.	Eligibility	14
esophageal cancer	DOID:5041	0-17
platinum	CHEBI:33364	69-77
Breast cancer- failure or intolerance of standard first-, second- and third-line chemotherapy consisting of a taxane and anthracycline. No indication or resistance to standard antihormonal treatment. No indication or resistance to human epidermal growth factor receptor (HER)-2-neu targeted therapy. No indication or resistance to irradiation and/or surgery.	Eligibility	15
breast	UBERON:0000310	0-6
taxane	CHEBI:36064	110-116
anthracycline	CHEBI:48120	121-134
growth factor	BAO:0002024	247-260
receptor	BAO:0000281	261-269
surgery	OAE:0000067	350-357
Within the last 2 weeks prior to study day 1, vital laboratory parameters must have been within the normal range, except for the following laboratory parameters, which must have been within the ranges specified:	Eligibility	16
day	UO:0000033	39-42
range	LABO:0000114	107-112
range	LABO:0000114	194-199
Absolute neutrophil count (ANC):  1,000/mm3	Eligibility	17
Platelet count:  75,000/mm3	Eligibility	18
platelet count	CMO:0000029	0-14
Alanine aminotransferase (ALT):  5 x upper limit of normal (ULN)	Eligibility	19
alanine	CHEBI:16449	0-7
x	LABO:0000148	35-36
Aspartate aminotransferase (AST):  5 x ULN	Eligibility	20
aspartate	CHEBI:29995	0-9
x	LABO:0000148	37-38
Total bilirubin:  2.5 x ULN	Eligibility	21
x	LABO:0000148	22-23
Creatinine:  2 mg/dL	Eligibility	22
creatinine	CHEBI:16737	0-10
Age  18 years.	Eligibility	23
age	PATO:0000011	0-3
Able and willing to give written informed consent.	Eligibility	24
Exclusion Criteria:	Eligibility	25
Clinically significant heart disease (New York Heart Association Class III or IV).	Eligibility	26
heart disease	DOID:114	23-36
heart	UBERON:0000948	23-28
heart	UBERON:0000948	47-52
Other serious illnesses, e.g., serious infections requiring antibiotics or bleeding disorders.	Eligibility	27
Subjects with serious intercurrent illness requiring hospitalization.	Eligibility	28
Known human immunodeficiency virus positivity.	Eligibility	29
immunodeficiency	HP:0002721	12-28
virus	BAO:0000232	29-34
Chemotherapy, radiation therapy or immunotherapy within 4 weeks prior to first dose of study agent (6 weeks for nitrosoureas).	Eligibility	30
Known autoimmune disease (rheumatoid arthritis, systemic lupus erythematosus), as these conditions might have interfered with the evaluation of the induced immune response. Subjects with vitiligo or melanoma-associated hypopigmentation were not excluded.	Eligibility	31
autoimmune disease	DOID:417	6-24
rheumatoid arthritis	HP:0001370,DOID:7148	26-46
systemic lupus erythematosus	HP:0002725,DOID:9074	48-76
immune response	GO:0006955	156-171
vitiligo	HP:0001045,DOID:12306	187-195
excluded	HP:0040285	245-253
Chronic use of immunosuppressive drugs such as systemic corticosteroids.	Eligibility	32
chronic	HP:0011010	0-7
Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.	Eligibility	33
skin cancer	DOID:4159	95-106
carcinoma	HP:0030731,DOID:305	120-129
Mental impairment that may have compromised the ability to give informed consent and comply with the requirements of the study.	Eligibility	34
Lack of availability for immunological and clinical follow-up assessments.	Eligibility	35
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing of study agent.	Eligibility	36
Pregnancy or breastfeeding.	Eligibility	37
Women of childbearing potential: Refusal or inability to use effective means of contraception.	Eligibility	38
Outcome Measurement:	Results	0
Number of Participants With Treatment-emergent Adverse Events (TEAEs)	Results	1
Analysis of treatment-emergent adverse events (TEAEs) reported from clinical laboratory tests, physical examinations, and vital signs from pre-treatment through 4 weeks after the last dose of study treatment.	Results	2
Time frame: Up to 3 months	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Cohort 1 (Safety Analysis Set)	Results	5
Arm/Group Description: Subjects received MBV twice weekly by subcutaneous injection at a starting dose of 250 EU (dose level 1), with intrasubject dose escalations for each subsequent administration in the absence of a DLT until the desired pyrogenic effect was observed.	Results	6
Overall Number of Participants Analyzed: 13	Results	7
Measure Type: Number	Results	8
Unit of Measure: participants  Any TEAE: 13	Results	9
Grade 3 TEAE: 3	Results	10
Grade 4 TEAE: 0	Results	11
Grade 5 TEAE (Death): 1	Results	12
death	OAE:0000632	14-19
Treatment-related TEAE: 9	Results	13
SAE: 1	Results	14
TEAE leading to withdrawal: 0	Results	15
Results 2:	Results	16
Arm/Group Title: Cohort 2 (Safety Analysis Set)	Results	17
Arm/Group Description: Subjects received MBV twice weekly by intralesional (preferred) or subcutaneous (if intralesional not possible) injection at the fixed dose (60,800 EU [dose level 6]) that was determined to be the pyrogenic dose level in Cohort 1.	Results	18
Overall Number of Participants Analyzed: 4	Results	19
Measure Type: Number	Results	20
Unit of Measure: participants  Any TEAE: 4	Results	21
Grade 3 TEAE: 2	Results	22
Grade 4 TEAE: 0	Results	23
Grade 5 TEAE (Death): 0	Results	24
death	OAE:0000632	14-19
Treatment-related TEAE: 3	Results	25
SAE: 1	Results	26
TEAE leading to withdrawal: 0	Results	27
Adverse Events 1:	Adverse Events	0
Total: 1/13 (7.69%)	Adverse Events	1
Rapid disease progression  [1]1/13 (7.69%)	Adverse Events	2
disease	DOID:4,OGMS:0000031	6-13
Increased pleural effusion  [2]0/13 (0.00%)	Adverse Events	3
pleural effusion	HP:0002202	10-26
Adverse Events 2:	Adverse Events	4
Total: 1/4 (25.00%)	Adverse Events	5
Rapid disease progression  [1]0/4 (0.00%)	Adverse Events	6
disease	DOID:4,OGMS:0000031	6-13
Increased pleural effusion  [2]1/4 (25.00%)	Adverse Events	7
pleural effusion	HP:0002202	10-26
